Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.

Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S.

Blood Coagul Fibrinolysis. 2010 Apr;21(3):256-61. doi: 10.1097/MBC.0b013e328337014c.

PMID:
20087172
2.

Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®).

Schaden E, Jilch S, Hacker S, Schober A, Kozek-Langenecker S.

Clin Chim Acta. 2012 Dec 24;414:202-5. doi: 10.1016/j.cca.2012.09.029.

PMID:
23041210
3.

Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.

Mittermayr M, Velik-Salchner C, Stalzer B, Margreiter J, Klingler A, Streif W, Fries D, Innerhofer P.

Anesth Analg. 2009 Mar;108(3):743-50. doi: 10.1213/ane.0b013e31818657a3.

PMID:
19224778
5.

Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.

Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.

Thromb Haemost. 2008 Feb;99(2):427-34. doi: 10.1160/TH07-04-0307.

PMID:
18278195
6.

Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.

Adelmann D, Wiegele M, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, Scharbert G, Kozek-Langenecker S, Schaden E.

Thromb Res. 2014 Oct;134(4):918-23. doi: 10.1016/j.thromres.2014.08.006.

PMID:
25179518
7.

Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study.

Mittermayr M, Margreiter J, Velik-Salchner C, Klingler A, Streif W, Fries D, Innerhofer P.

Br J Anaesth. 2005 Sep;95(3):310-6.

8.

Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.

Feuring M, Wehling M, Schultz A.

Clin Exp Pharmacol Physiol. 2011 Nov;38(11):783-6. doi: 10.1111/j.1440-1681.2011.05593.x.

PMID:
21883380
9.

Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.

Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H.

J Clin Pharmacol. 2008 Oct;48(10):1189-96. doi: 10.1177/0091270008322911.

PMID:
18716314
10.

The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures.

El Rouby S, Cohen M, Gonzales A, Hoppensteadt D, Lee T, Zucker ML, Khalid K, Laduca FM, Fareed J.

J Thromb Thrombolysis. 2006 Apr;21(2):137-45.

PMID:
16622609
11.

Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.

Saw J, Kereiakes DJ, Mahaffey KW, Applegate RJ, Braden GA, Brent BN, Brodie BR, Groce JB, Levine GN, Leya F, Moliterno DJ.

Thromb Res. 2003;112(5-6):301-6.

PMID:
15041274
12.

Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.

Sucker C, Zotz RB, Görlinger K, Hartmann M.

Acta Anaesthesiol Scand. 2008 Mar;52(3):358-62. doi: 10.1111/j.1399-6576.2007.01550.x.

PMID:
18205897
13.

Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.

Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M.

Am J Clin Pathol. 2008 Sep;130(3):446-54. doi: 10.1309/Q0G21Y26UR0UHQ1A.

14.

The influence of laboratory coagulation tests and clotting factor levels on Rotation Thromboelastometry (ROTEM(R)) during major surgery with hemorrhage.

Theusinger OM, Schröder CM, Eismon J, Emmert MY, Seifert B, Spahn DR, Baulig W.

Anesth Analg. 2013 Aug;117(2):314-21. doi: 10.1213/ANE.0b013e31829569ac.

PMID:
23780419
15.

Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.

Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, Cayla G, Gallois V, Galier S, Costagliola D, Collet JP, Montalescot G.

J Am Coll Cardiol. 2010 Feb 16;55(7):617-25. doi: 10.1016/j.jacc.2009.08.077.

16.

Validation of rotational thromboelastometry during cardiopulmonary bypass: A prospective, observational in-vivo study.

Gronchi F, Perret A, Ferrari E, Marcucci CM, Flèche J, Crosset M, Schoettker P, Marcucci C.

Eur J Anaesthesiol. 2014 Feb;31(2):68-75. doi: 10.1097/EJA.0b013e328363171a.

PMID:
23867776
17.

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.

Thromb Haemost. 2010 Apr;103(4):815-25. doi: 10.1160/TH09-03-0176.

PMID:
20135059
18.

Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?

Gertler R, Wiesner G, Tassani-Prell P, Braun SL, Martin K.

J Cardiothorac Vasc Anesth. 2011 Dec;25(6):981-6. doi: 10.1053/j.jvca.2010.11.020.

PMID:
21315618
19.

Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.

Harder S, Parisius J, Picard-Willems B.

Thromb Res. 2008;123(2):396-403. doi: 10.1016/j.thromres.2008.05.010.

PMID:
18571698
Items per page

Supplemental Content

Support Center